ClinicalTrials.gg
Drug

Pimavanserin clinical trials

Also written Nuplazid and ACP-103.

studies test it
43
open now
9
in phase 3
15
first study started
2004

How each study uses pimavanserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pimavanserin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Apr 2016 · NUPLAZID · NDA 207318 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pimavanserin
25
Pimavanserin 34 mg
4
Pimavanserin tartrate (ACP-103)
4
pimavanserin tartrate
3
Pimavanserin 20 mg
2

Development codes

ACP-103
5

Other names

Nuplazid
13

Studies by the year they started

43 studies that test it; most in 2022 (5)

Studies that test pimavanserin, by start year
YearStudies
20043
20051
20072
20081
20101
20131
20164
20173
20184
20193
20204
20225
20234
20243
20253
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
2
Phase 2
20
Phase 3
15
Phase 4
6
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 27 · Other 16

ACADIA Pharmaceuticals Inc. (25) · Baylor College of Medicine (2) · VA Office of Research and Development (2) · Tasly Pharmaceutical Group Co., Ltd (1) · University Hospital, Strasbourg, France (1) · Humanis Saglık Anonim Sirketi (1) · Joseph Jankovic (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)

Often tested with

Tested in the same studies.

Quetiapine (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test pimavanserin.

Studies

Open first, then newest update. How each study uses pimavanserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 43

See all 43 studies that test pimavanserin →

Given beside what is tested · 2 — pimavanserin is usual care or a partner of the new treatment

Codes

What other systems call pimavanserin · ClinicalTrials.gg INT004917

  • MeSH (NLM) C510793pimavanserinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) JZ963P0DIKPIMAVANSERINConfirmed FDA, NLM, Wikidata
  • RxNorm 1791685Confirmed FDA, Wikidata
  • Wikidata Q7194603pimavanserinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C76444PimavanserinOne source FDA
  • DrugBank DB05316One source Wikidata

Also registered as pimavanserin tartrate (UNII NA83F1SJSR · RxNorm 1791686).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.